NICM
AVDL

Neo Ivy Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Neo Ivy Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-159,165
Closed -$3.43M – 343
2025
Q4 		$3.43M Buy
+159,165
New +$3.09M 0.54% 78

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Neo Ivy Capital Management's AVDL Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 159,165 shares — an estimated $3.43M sold.

Neo Ivy Capital Management first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $3.43M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Neo Ivy Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 159,165 Avadel Pharmaceuticals shares in Q1 2026, an estimated $3.43M.
  • Neo Ivy Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Neo Ivy Capital Management's Avadel Pharmaceuticals position peaked at $3.43M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.